

Please complete the ABSTRACT TEMPLATE online, for Biomed 2023 Company Presentations

**ABSTRACT TEMPLATE: CHECKLIST AND INSTRUCTIONS**

Company name-Cell-Lipo LTD--- \* Website [www.cell-lipo.com](http://www.cell-lipo.com) \*

CEO name Ofer Barshem \* Cell phone number 0526045186 \*

Select a CATEGORY: Medical Devices

Select up to two SESSIONS per abstract from the list below \*

13. Skin health and Beauty

○ **Executive Summary / Investment Rational**

Autologous fat grafting is a fast-growing aesthetics segment, as younger patients are seeking natural & long-lasting solutions. Cell-Lipo have licensed a proprietary stem cell isolation technology from Ichilov hospital, & a novel laser assisted liposuction technology, jointly aiming to dramatically improve long term fat grafting results. The founding team hosts industry leaders in science, R&D, strategic collaborations & funding.

○ **Core Technology**

Autologous fat is widely used as a filler, but result verry, as significant part of the fat is gradually lost. Supplying high vitality fat cells, harvested with laser assisted liposuction, produces a superior “row material”. The same adipose tissue is mechanically processed (without enzymes) for SVF isolation, added to the implanted fat, making it highly potent, improving long term results.

○ **Product Profile/Pipeline**

A combined closed in-clinic fat transfer system is being developed, based on proven prototypes that have been clinically evaluated. Cell-Lipo initiated discussions with several strategic aesthetics players for an exclusive licensing agreement. Initial sales are expected within 12 months, with expansion upon regional regulatory approvals. In a \$5b +10% CAGR market, seeking robust accessible solutions, Cell-Lipo gains continues positive attention.

○ **Business Strategy**

Cell-Lipo will offer a competitive system & per case consumables, that can be easily handled by a standard organic clinic team. The attractive value proposition- long lasting fat transfer, attract patients & allow doctors to generate additional revenues. Regional distributors will sell locally, aiming for a strategic licensing partnership for the US or global market. Other, non-aesthetics applications will be developed.

- **What's Next?**

Funding: pre-A round \$1m for the following goals:

- R&D: design freeze within 12 months.
- Clinical: ongoing trial in Ichilov to establish our scientific claim.
- Regulatory: pre-submission to the FDA.

Round A - \$10m for expiation, ramp up & GoToMarket.

Long term developments- SVF treatment for knee osteoarthritis & other ortho disorders, & wound-care. Each vertical is a separated business.